Hemp and Insomnia: What Meta-Analyses Have Shown and What They Haven't Measured

What Have Meta-Analyses Shown About Hemp in Sleep Disorders?

A moderate effect on paper and a wide spread underneath. Three systematic reviews with meta-analysis consistently see an improvement in sleep ratings after cannabinoids compared to placebo, but some confidence intervals brush against zero, and the variability between studies is so large that the average describes more a range of results than a typical patient.

The latest of these works, a systematic review with a meta-analysis of six randomized studies involving 1077 participants (Sleep Medicine Reviews, 2025, PMID:40929927), reports an advantage of cannabinoids over placebo in subjective sleep quality at a level of 0.53 standard deviations, with a confidence interval from 0.03 to 1.02. In a narrower subgroup of people with insomnia or poor sleep quality, the result rises to 0.60, with a range from 0.09 to 1.11. The lower limit of both intervals lies just above zero, so the same data allow for a moderate effect just as well as one that is practically invisible.

This same work separates the preparations, and this separation says more than the average. Where something other than pure cannabidiol was administered, the effect reaches 0.82 with a range from 0.24 to 1.40. Pure cannabidiol gives 0.13 with a range from minus 0.38 to 0.65, which is statistically insignificant. Averaging two such different interventions gives a number that does not describe either of them, and the strain name does not appear in this division at all.

Why do the same data yield such different conclusions?

Because the variability between studies skews the result. The heterogeneity in the 2025 meta-analysis reaches 88 to 89 percent, in the 2026 review, a high risk of systematic error is present in 44 percent of the included works, and studies differ in preparation, dosage, and method of measuring sleep more than they differ from placebo.

Heterogeneity indicates what portion of the variability between studies arises from real differences rather than chance. A value close to ninety percent means that the results of individual works diverge almost entirely due to what those works differed in: preparation, dosage, length of observation, and the condition of participants. An average calculated from such a collection is a numerically correct figure, yet it does not describe any single study.

The risk of systematic error is the second layer of the same problem. In the 2026 review, which included 54 randomized studies and 2477 participants, a high risk of error was attributed to 44 percent of the included works. This does not mean that their results are untrue; it means that the way they were conducted allows for a shift in the result towards an effect that was not present.

None of these works studied dried flower issued in Polish pharmacies or any single strain. They examined preparations with known dosages: nabilone, cannabidiol, and standardized extracts. The improvement pertains to the rating given by the patient in the questionnaire, not the measured structure of sleep, and the variability of results between studies exceeds what a meta-analysis can average. There was no evidence that the strain name predicted anything about sleep.

Does the improvement pertain to measured sleep or assessed in a survey?

Both, but not to the same degree and not in the same works. The 2026 review found an extension of sleep recorded by electronic devices in people with insomnia, while earlier works relied on questionnaires filled out by patients. These are two different measures, and their agreement can be weak.

The 2026 review, based on 54 randomized studies, reports for people with insomnia an extension of sleep by 0.54 standard deviations in recordings from electronic devices and 0.55 in diaries kept by patients. Both measures turned out similarly, but the lower limit of the range for the diary is 0.01, which is practically zero.

An earlier systematic review with a meta-analysis of five studies, two of which had randomization and three did not (CNS Drugs, 2020, PMID:33244728), is mainly based on questionnaires. Three studies without randomization showed an improvement in the Pittsburgh scale by 1.89 points by the fourth week in 176 participants and by 2.41 points in the eighth week in 166 participants. One randomized, double-blind study involving 32 people showed an advantage of nabilone over amitriptyline by 3.25 points on the insomnia severity scale after two weeks. A study without randomization and without a control group does not distinguish the effect of the preparation from the natural course of insomnia, so the first two numbers weigh less than the third.

What strain characteristics are important here?

None, as far as we are asking for evidence. In sleep studies, preparations with known dosages were administered, not dried flower with a brand name, so there is no work that compared two strains with each other in this indication. The characteristics most often mentioned are chemotype and terpene composition, and both remain hypotheses.

Chemotype, meaning which cannabinoid dominates in the raw material, is the only characteristic that meta-analyses say anything about, and they say something inconvenient for strain catalogs. In the 2025 review, preparations containing something more than pure cannabidiol performed significantly better than those with pure cannabidiol, but the comparison concerned ready-made preparations with known dosages, not dried flower with declared tetrahydrocannabinol content. Transferring this result to dried flower would require the assumption that the dosage given in the study corresponds to the dosage inhaled from a vaporizer, and no one measured that.

The terpene profile is sometimes cited as an explanation for differences between strains described as nighttime, but in sleep studies, no one controlled it. Separate texts in this series gather what is known about mircenie oraz o linalool. In the data collected for this service, two public databases provide different compositions for most commonly described strains, so the declared profile may be a feature of the source, not the plant. How to read such a description is explained in a separate strain profile guide.

How long does the effect last after vaporization, and how long after ingestion?

After vaporization, it lasts shorter than the night, while after ingestion, it lasts longer. In cases of sleep problems, this difference translates to whether the episode will involve just falling asleep or extend into the next morning. The course is determined by the method of administration established by the doctor, not by the name of the raw material printed on the package.

The route of administration determines the course more than the variety itself. After vaporization, the substance passes from the lungs to the blood almost immediately, so the first sensations appear after a few minutes, the intensity increases for another ten to thirty minutes, and the whole effect lasts for two to four hours. After ingestion, the raw material first passes through the intestine and liver, so the first sensations are awaited from half an hour to two hours, and the episode can last six, sometimes eight hours. Hence the most common mistake with oral administration: anyone who thinks nothing is happening after thirty minutes and takes another dose will receive both doses at once. The above ranges describe the route of administration, not this variety; pharmacokinetic studies for a single cultivar have not been published.

In sleep studies, preparations with a known dose were administered. With dried flower, such certainty does not exist: the amount absorbed depends on the method of administration, not on the number printed on the package. Why the device setting does not equal the temperature of the raw material is explained in a separate tekst tego cyklu.

What does the doctor decide, and what does the patient decide?

The indication, preparation, and dose are determined by the attending physician, as dried flower is a pharmaceutical raw material dispensed in the Rpw category, meaning by prescription with a secondary prescription. The patient decides whether to even go to the doctor with this and what to say about their previous treatment and other medications taken.

European guidelines for insomnia prioritize cognitive-behavioral therapy, and pharmacological treatment is described as a step taken together with the doctor when the first approach is insufficient. Dried flower does not have a registered indication for sleep disorders in Poland: it is a raw material from which the pharmacy prepares medication based on a prescription, and the assessment of a specific case is up to the attending physician. This order describes someone else's document, not a recommendation from this site: no description in the store establishes an indication or determines whether the first approach has been exhausted.

The patient brings to this conversation things that the doctor cannot read from any database: the course of previous treatment, a list of medications taken, and what really happens at night. Without this part, no meta-analysis translates to an individual case, as the averaged result knows nothing about the person sitting in the office. The dispensing mode is described separately. text on obtaining a prescription for medical marijuana, and a list of items available in a given month is collected a compilation of currently available strains.

What adverse effects have been reported in sleep studies?

More frequent than in the placebo group. In a systematic review with a meta-analysis of 54 randomized studies (2477 participants, The Lancet Psychiatry, 2026, PMID:41856154), the odds ratio for any adverse event was 1.75, with a range from 1.25 to 2.46, which corresponds to one additional person with an event for every seven treated.

Reports of adverse effects are collected for medicinal products with a batch number, not for the strain name, so the following pertains to hemp dried flower as a group of raw materials. The most frequently reported symptoms are dry mouth, red eyes, and increased heart rate. Dizziness upon rapid standing, daytime drowsiness, and temporary worsening of short-term memory are less frequently described, as well as anxiety that increases with dosage. A separate issue is medications taken concurrently, especially sedatives and those affecting coagulation: their assessment requires knowledge of the entire list of preparations, not just the description of the plant. We do not provide the frequency of these symptoms numerically, as public compilations for hemp dried flower in Poland do not separate them by individual products.

The above ratio describes events of any kind, not their severity, and comes from studies on preparations with a known dose, not on dried flower dispensed in pharmacies. What is known about cannabinoids in anxiety disorders is collected in a separate tekst tego cyklu, as anxiety can simultaneously be a cause of poor sleep and a reported adverse effect. The state of evidence regarding lack of appetite is collected in another tekst tego cyklu, where the research results diverge more from common belief than here.

Frequently Asked Questions

Is dried flower a registered medication for insomnia?

No. Dried flower is a pharmaceutical raw material dispensed by a doctor's prescription in the Rpw category, not a ready-made medication with a registered indication for sleep disorders. The attending physician determines its use in a specific case.

Do strains described as nighttime work better for sleep than others?

It is unknown. None of the discussed studies compared strains with each other, and the division into daytime and nighttime strains comes from commercial descriptions, not from research. It has not been shown that the strain name predicts anything about sleep.

What does a heterogeneity of 88 to 89 percent mean?

That the results of individual studies diverge almost entirely due to actual differences between them, and not due to chance. The average calculated from such a set is mathematically correct, but does not describe any of the averaged studies.

Does cannabidiol itself improve sleep quality?

In a systematic review with a meta-analysis of six randomized studies (PMID:40929927), cannabidiol alone yielded 0.13 standard deviations with a range from minus 0.38 to 0.65, which is a statistically insignificant result. Products containing more performed better.

In these studies, was sleep measured by a device, or was it only asked about by the patient?

Both methods were used. A review from 2026 (PMID:41856154) describes an extension of sleep recorded by an electronic device, while older works rely on questionnaires filled out by the patient. None of these meta-analyses summarize the measured structure of sleep.

Who decides on the use of dried flower for sleep issues?

The attending physician. The dried flower is dispensed by prescription from a doctor in the Rpw category, so the indication, product, and dosage are determined by them, not by the description on the store's website. This text describes the state of evidence and is not a therapeutic recommendation.

The material is for informational purposes and does not replace medical advice. Dried flower is a pharmaceutical raw material dispensed exclusively by prescription from a doctor in the Rpw category. Editorial text: redakcja ubucha.pl.